TL 118

Drug Profile

TL 118

Alternative Names: Angiogenesis inhibitors - Tiltan Pharma; Hamsa 1; Hamsa-1™ TL-118; TL-111; TL-112

Latest Information Update: 21 Mar 2016

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Tiltan Pharma
  • Class Nonsteroidal anti-inflammatories; Sulfonamides
  • Mechanism of Action Alkylating agents; Angiogenesis inhibitors; Histamine H2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer; Prostate cancer

Most Recent Events

  • 04 Feb 2016 Tiltan Pharma completes enrolment in its phase IIb trial for Pancreatic cancer (Adjuvant therapy, Metastatic disease) in Israel and USA (PO) (NCT01509911)
  • 10 Aug 2015 Tiltan Pharma completes a phase IIb trial in Prostate cancer (Metastatic disease) in Israel prior to this date (NCT00684970)
  • 05 Feb 2014 Phase II development in Pancreatic cancer (Adjuvant therapy, Metastatic disease) is ongoing in Israel and USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top